Thomas Jensen
Vorstandsvorsitzender bei Aloop Therapeutics ApS
Ursprung des Netzwerks ersten Grades von Thomas Jensen
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 20 | |
Aloop Therapeutics ApS
 Aloop Therapeutics ApS Pharmaceuticals: MajorHealth Technology Aloop Therapeutics ApS manufactures pharmaceutical preparations. The company is based in Copenhagen, Denmark. The CEOs are Søren Sylvester Skjærbæk, Thomas Kirkegaard Jensen. The Danish company was founded in 2022.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Thomas Jensen
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Chairman Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| Technical University of Denmark | College/University | Graduate Degree Corporate Officer/Principal Doctorate Degree | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Azanta A/S
 Azanta A/S Pharmaceuticals: MajorHealth Technology Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Private Equity Investor | |
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Director/Board Member Director/Board Member | |
Inthera Bioscience AG
 Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member Chief Executive Officer | |
Bankinvest Biomedical Venture
 Bankinvest Biomedical Venture Investment ManagersFinance Bankinvest Biomedical Venture provides investment services. The company was founded in 1998 and is headquartered in Copenhagen, Denmark. | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal | |
| Copenhagen Business School | College/University | Graduate Degree Undergraduate Degree | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Flamingo Therapeutics BV
 Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Chief Executive Officer Chairman | |
| ABLYNX | Biotechnology | Chairman Director/Board Member | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Zymenex A/S
 Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Biotechnology | Director/Board Member Chairman | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
Dynacure SA
 Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Chairman Director/Board Member | |
| SUPERNUS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Chairman Chief Executive Officer | |
| Alliance for Biosecurity | Chairman | ||
| MORGAN STANLEY | Investment Managers | Corporate Officer/Principal | |
| INNATE PHARMA | Pharmaceuticals: Major | Corporate Officer/Principal | |
ALK-Abelló BV
 ALK-Abelló BV Pharmaceuticals: MajorHealth Technology Part of ALK-Abello A/S, ALK-Abelló BV is a Dutch company that has been providing various allergy treatments since 1923. The company has developed an adrenaline auto-injector for the emergency treatment of acute severe allergic reactions. ALK-Abelló BV offers job opportunities for individuals who are passionate about making a difference in the field of allergies. | Pharmaceuticals: Major | Chairman | |
STJ Advisors LLP
 STJ Advisors LLP Investment ManagersFinance STJ Advisors LLP provides capital markets advisory services. The private company is based in London, UK and has subsidiaries in Hong Kong. The British company was founded in 2008 by John James Moore St. John. | Investment Managers | Corporate Officer/Principal | |
ALK-Abelló Ltd.
 ALK-Abelló Ltd. Pharmaceuticals: MajorHealth Technology ALK-Abelló Ltd. engages in selling, marketing and distributing pharmaceutical products. The company is headquartered in Reading, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
| ALK Sverige AB | Chairman | ||
| NOVO NORDISK A/S | Pharmaceuticals: Major | Sales & Marketing | |
| ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member | |
ALK-Abelló SpA
 ALK-Abelló SpA Pharmaceuticals: MajorHealth Technology ALK-Abelló SpA engages in the manufacture of anti-allergy products. It offers drugs for symptomatic treatment and allergen-specific immunotherapy. The company is headquartered in Lainate, Italy. | Pharmaceuticals: Major | Chairman | |
| BAVARIAN NORDIC A/S | Pharmaceuticals: Major | Chief Executive Officer | |
| ALK-ABELLÓ A/S | Biotechnology | Chairman | |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Chief Executive Officer | |
| Nova School of Business & Economics | College/University | Graduate Degree | |
| GENKYOTEX SA. | Pharmaceuticals: Major | Director/Board Member |
Statistik
International
| Dänemark | 18 |
| Frankreich | 8 |
| Niederlande | 6 |
| Vereinigte Staaten | 6 |
| Vereinigtes Königreich | 5 |
Sektoral
| Health Technology | 37 |
| Finance | 6 |
| Consumer Services | 5 |
| Commercial Services | 3 |
| Health Services | 2 |
Operativ
| Director/Board Member | 179 |
| Corporate Officer/Principal | 51 |
| Chairman | 49 |
| Independent Dir/Board Member | 49 |
| Chief Executive Officer | 35 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Bo Jesper Hansen | 34 |
| Georges Gemayel | 33 |
| Martijn Kleijwegt | 33 |
| Anders Hedegaard | 30 |
| Rémi Droller | 29 |
| Catherine Moukheibir | 29 |
| Sten Verland | 28 |
| Martin N. Bonde | 22 |
| Emmanuelle Coutanceau | 21 |
| Kim Stratton | 14 |
| Anders Hinsby | 14 |
| Anders Fink Vadsholt | 13 |
| Carrolee Barlow | 12 |
| Stephanie Okey | 9 |
| Camilla Hansen | 7 |
- Börse
- Insiders
- Thomas Jensen
- Unternehmensverbindungen
